8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Mar 16, 2026·SEC
Material company update
Mar 12, 2026·SEC
Seres Therapeutics, Inc.(MCRB)Earnings, Financials & Key Ratios
MCRB•NASDAQ
$7.72
$74M mkt cap·12.1× P/E·Price updated May 7, 2026
AboutSeres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$789K
- EBITDA-$90M+22.5%
- Net Income$6M+4088.2%
- EPS (Diluted)0.64+103.4%
- Gross Margin-423.83%
- EBITDA Margin-11386.31%
- Operating Margin-11910.14%
- Net Margin721.93%
- ROE19.64%+1890.5%
- ROIC-90.33%+50.1%
- Debt/Equity1.88-71.8%
MCRB Key Insights
Seres Therapeutics, Inc. (MCRB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 109.6% free cash flow margin
- ✓Healthy 5Y average net margin of 338.3%
✗Weaknesses
- ✗Weak momentum: RS Rating 8 (bottom 8%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Sales declining 52.7% over 5 years
- ✗Shares diluted 14.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MCRB Price & Volume
Seres Therapeutics, Inc. (MCRB) stock price & volume — 10-year historical chart
Loading chart...
MCRB Growth Metrics
Seres Therapeutics, Inc. (MCRB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-52.67%
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-164.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM48.25%
Return on Capital
10 Years-62.37%
5 Years-63.7%
3 Years-76.23%
Last Year-86.43%
MCRB Recent Earnings
Seres Therapeutics, Inc. (MCRB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 1/12 qtrs (17%)
Q2 2026Latest
May 5, 2026EPS
$2.08
Est $1.88
-10.6%
Revenue
$358,000
Est $358,000
+0.0%
Q2 2026
Mar 12, 2026EPS
$1.89
Est $2.39
+20.9%
Revenue
$438,000
Est $5M
-91.7%
Q4 2025
Nov 5, 2025EPS
$0.94
Est $0.05
+1780.0%
Revenue
$351,000
Est $8M
-95.5%
Q3 2025
Aug 6, 2025EPS
$2.27
Est $2.72
+16.5%
Revenue
—
Est $6M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $2.08vs $1.88-10.6% | $358,000vs $358,000+0.0% |
| Q2 2026 | Mar 12, 2026 | $1.89vs $2.39+20.9% | $438,000vs $5M-91.7% |
| Q4 2025 | Nov 5, 2025 | $0.94vs $0.05+1780.0% | $351,000vs $8M-95.5% |
| Q3 2025 | Aug 6, 2025 | $2.27vs $2.72+16.5% | —vs $6M |
Based on last 12 quarters of dataView full earnings history →
MCRB Peer Comparison
Seres Therapeutics, Inc. (MCRB) competitors in Microbiome and Phage Therapeutics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 MIRM | 5.17B | 102.93 | -219 | 54.74% | -194.97% | -289.33% | 1.02 | |
 ARWR | 10.92B | 77.95 | -6389.34 | 232.58% | -48.38% | -55.47% | 0.73 | |
 RCKT | 397.53M | 3.67 | -1.83 | -80.49% | 0.09 | |||
 EVGN | 6.81M | 0.78 | -0.27 | 50.9% | -52.33% | -19.33% | 0.87 | |
 ACAD | 3.86B | 22.57 | 9.85 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 NBIX | 15.01B | 149.59 | 32.03 | 21.45% | 21.55% | 21.64% | 0.13 |
Compare MCRB vs Peers
Seres Therapeutics, Inc. (MCRB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MCRB Income Statement
Seres Therapeutics, Inc. (MCRB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 32.1M | 28.27M | 34.51M | 33.22M | 144.93M | 0 | 0 | 0 | 789K | 1.15M |
| Revenue Growth % | 47.48% | -11.94% | 22.07% | -3.74% | 336.33% | -100% | - | - | - | - |
| Cost of Goods Sold | 89.45M | 95.95M | 0 | 90.57M | 0 | 0 | 0 | 3.53M | 4.13M | 606K |
| COGS % of Revenue | 278.68% | 339.46% | - | 272.68% | - | - | - | - | 523.83% | - |
| Gross Profit | -57.35M▲ 0% | -67.69M▼ 18.0% | 34.51M▲ 151.0% | -57.35M▼ 266.2% | 144.93M▲ 352.7% | 0▼ 100.0% | 0▲ 0% | -3.53M▲ 0% | -3.34M▲ 5.3% | 183K▲ 0% |
| Gross Margin % | -178.68% | -239.46% | 100% | -172.68% | 100% | - | - | - | -423.83% | 15.95% |
| Gross Profit Growth % | 4.76% | -18.02% | 150.98% | -266.22% | 352.68% | -100% | - | - | 5.32% | - |
| Operating Expenses | 123.5M | 128.55M | 106.38M | 30.77M | 209.42M | 179.91M | 195.1M | 117.78M | 90.63M | 88.18M |
| OpEx % of Revenue | 384.72% | 454.77% | 308.31% | 92.65% | 144.5% | - | - | - | 11486.31% | - |
| Selling, General & Admin | 34.04M | 32.6M | 24.75M | 30.77M | 69.26M | 70.26M | 77.5M | 53.18M | 39.16M | 35.34M |
| SG&A % of Revenue | 106.04% | 115.31% | 71.72% | 92.65% | 47.79% | - | - | - | 4962.74% | - |
| Research & Development | 89.45M | 95.95M | 80.14M | 90.57M | 141.89M | 109.65M | 117.6M | 64.6M | 49.06M | 37.82M |
| R&D % of Revenue | 278.68% | 339.46% | 232.26% | 272.68% | 97.91% | - | - | - | 6218% | - |
| Other Operating Expenses | 425K | 170K | 1.49M | -90.57M | -1.73M | 0 | 0 | 0 | 2.41M | 1.63M |
| Operating Income | -91.39M▲ 0% | -100.28M▼ 9.7% | -71.88M▲ 28.3% | -88.13M▼ 22.6% | -64.49M▲ 26.8% | -179.91M▼ 179.0% | -195.1M▼ 8.4% | -121.31M▲ 37.8% | -93.97M▲ 22.5% | -87.64M▲ 0% |
| Operating Margin % | -284.72% | -354.77% | -208.31% | -265.33% | -44.5% | - | - | - | -11910.14% | -7640.98% |
| Operating Income Growth % | 1.56% | -9.73% | 28.33% | -22.61% | 26.82% | -178.97% | -8.44% | 37.82% | 22.54% | - |
| EBITDA | -84.14M | -92.42M | -64.27M | -79.24M | -58.55M | -173.28M | -188.85M | -115.85M | -89.84M | -83.39M |
| EBITDA Margin % | -262.11% | -326.96% | -186.27% | -238.56% | -40.4% | - | - | - | -11386.31% | -7270.18% |
| EBITDA Growth % | 5.07% | -9.85% | 30.46% | -23.28% | 26.11% | -195.98% | -8.98% | 38.66% | 22.45% | 23.59% |
| D&A (Non-Cash Add-back) | 7.26M | 7.86M | 7.6M | 8.89M | 5.95M | 6.63M | 6.24M | 5.47M | 4.13M | 4.25M |
| EBIT | -89.38M | -98.94M | -69.78M | -86.2M | -62.67M | -177.56M | -187.66M | -125.77M | -93.97M | -31.03M |
| Net Interest Income | 1.59M | 1.17M | 531K | -1.98M | -40K | -2.96M | -5.88M | 3.97M | 2.23M | 1.61M |
| Interest Income | 0 | 0 | 1.03M | 946K | 2.87M | 3.06M | 7.3M | 3.97M | 2.23M | 1.93M |
| Interest Expense | 1.59M | 1.17M | 502K | 2.92M | 2.91M | 6.02M | 13.18M | 0 | 0 | 0 |
| Other Income/Expense | 2.02M | 1.34M | 1.6M | -997K | -1.08M | -3.67M | 4.97M | -4.46M | 99.67M | 40.74M |
| Pretax Income | -89.38M▲ 0% | -98.94M▼ 10.7% | -70.28M▲ 29.0% | -89.13M▼ 26.8% | -65.58M▲ 26.4% | -183.58M▼ 179.9% | -190.13M▼ 3.6% | -125.77M▲ 33.8% | 5.7M▲ 104.5% | -46.9M▲ 0% |
| Pretax Margin % | -278.44% | -350.03% | -203.68% | -268.33% | -45.25% | - | - | - | 721.93% | -4088.84% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -89.38M▲ 0% | -98.94M▼ 10.7% | -70.28M▲ 29.0% | -89.13M▼ 26.8% | -65.58M▲ 26.4% | -250.16M▼ 281.5% | -113.72M▲ 54.5% | 136K▲ 100.1% | 5.7M▲ 4088.2% | -46.9M▲ 0% |
| Net Margin % | -278.44% | -350.03% | -203.68% | -268.33% | -45.25% | - | - | - | 721.93% | -4088.84% |
| Net Income Growth % | 2.4% | -10.7% | 28.97% | -26.82% | 26.42% | -281.46% | 54.54% | 100.12% | 4088.24% | -164.29% |
| Net Income (Continuing) | -89.38M | -98.94M | -70.28M | -89.13M | -65.58M | -183.58M | -190.13M | -125.77M | 5.7M | -46.9M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | -66.58M | 76.41M | 125.91M | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -44.19▲ 0% | -48.57▼ 9.9% | -24.81▲ 48.9% | -22.34▲ 10.0% | -14.30▲ 36.0% | -46.29▼ 223.7% | -17.77▲ 61.6% | -18.86▼ 6.1% | 0.64▲ 103.4% | -4.89▲ 0% |
| EPS Growth % | 3.93% | -9.9% | 48.91% | 9.96% | 35.99% | -223.71% | 61.61% | -6.13% | 103.39% | 48.25% |
| EPS (Basic) | -44.19 | -48.57 | -24.81 | -22.34 | -14.30 | -46.29 | -17.77 | -18.86 | 0.64 | - |
| Diluted Shares Outstanding | 2.02M | 2.04M | 2.83M | 3.99M | 4.59M | 5.4M | 6.4M | 7.77M | 8.87M | 9.58M |
| Basic Shares Outstanding | 2.02M | 2.04M | 2.83M | 3.99M | 4.59M | 5.4M | 6.4M | 7.77M | 8.86M | 9.58M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MCRB Balance Sheet
Seres Therapeutics, Inc. (MCRB) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 155.08M | 92.67M | 100.19M | 268.78M | 303.63M | 194.76M | 175.41M | 38.67M | 49.38M | 31.84M |
| Cash & Short-Term Investments | 149.98M | 85.82M | 94.82M | 253.62M | 290.71M | 181.34M | 127.97M | 30.79M | 45.77M | 29.83M |
| Cash Only | 36.09M | 85.82M | 65.13M | 116.05M | 180M | 163.03M | 127.97M | 30.79M | 45.77M | 29.83M |
| Short-Term Investments | 113.89M | 0 | 29.69M | 137.57M | 110.7M | 18.31M | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 1.78M | 9.39M | 0 | 0 | 0 | 4.75M | 360K | 233K |
| Days Sales Outstanding | - | - | 18.88 | 103.15 | - | - | - | - | 166.54 | 179.16 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 29.65M | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 6.84M | 0 | 0 | 0 | 13.42M | 17.8M | 3.13M | 3.25M | 1.77M |
| Total Non-Current Assets | 34.44M | 27.81M | 32.25M | 74.16M | 51.23M | 154.02M | 183.19M | 101.14M | 88.82M | 85.78M |
| Property, Plant & Equipment | 32.93M | 26.29M | 30.85M | 22.94M | 36.15M | 133.97M | 108.03M | 92.44M | 80.12M | 77.08M |
| Fixed Asset Turnover | 0.97x | 1.08x | 1.12x | 1.45x | 4.01x | - | - | - | 0.01x | 0.01x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 1.51M | 1.4M | 0 | 49.83M | 495K | 9.59M | 0 | 0 | 8.67M | 26M |
| Other Non-Current Assets | 0 | 113K | 1.4M | 1.4M | 14.59M | 10.46M | 75.16M | 8.7M | 31K | 8.79M |
| Total Assets | 189.52M▲ 0% | 120.47M▼ 36.4% | 132.44M▲ 9.9% | 342.94M▲ 158.9% | 354.86M▲ 3.5% | 348.78M▼ 1.7% | 358.6M▲ 2.8% | 139.81M▼ 61.0% | 138.19M▼ 1.2% | 117.62M▲ 0% |
| Asset Turnover | 0.17x | 0.23x | 0.26x | 0.10x | 0.41x | - | - | - | 0.01x | 0.01x |
| Asset Growth % | -30.49% | -36.43% | 9.93% | 158.94% | 3.48% | -1.71% | 2.81% | -61.01% | -1.16% | -104.55% |
| Total Current Liabilities | 31.63M | 42.04M | 45.99M | 46.41M | 82.26M | 85.6M | 98.66M | 41.22M | 19.32M | 19.34M |
| Accounts Payable | 7.03M | 6.42M | 4.86M | 4.02M | 13.73M | 17.44M | 3.64M | 4.08M | 1.68M | 2.34M |
| Days Payables Outstanding | 28.7 | 24.4 | - | 16.19 | - | - | - | 421.53 | 148.54 | 1.19K |
| Short-Term Debt | 0 | 0 | 0 | 454K | 0 | 456K | 0 | 0 | 10.39M | 10.87M |
| Deferred Revenue (Current) | 12.08M | 20.42M | 25.79M | 22.6M | 16.82M | 4.26M | 7.73M | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 21.1M | 34.77M | 59.19M | 0 | 4.57M | 6.14M |
| Current Ratio | 4.90x | 2.20x | 2.18x | 5.79x | 3.69x | 2.28x | 1.78x | 0.94x | 2.56x | 2.56x |
| Quick Ratio | 4.90x | 2.20x | 2.18x | 5.79x | 3.69x | 2.28x | 1.48x | 0.94x | 2.56x | 2.56x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.01K |
| Total Non-Current Liabilities | 97.2M | 126.48M | 134.77M | 121.78M | 141.09M | 252.41M | 304.8M | 84.8M | 74.65M | 71.78M |
| Long-Term Debt | 0 | 0 | 24.65M | 24.64M | 24.64M | 50.59M | 101.54M | 0 | 0 | 69.63M |
| Capital Lease Obligations | 0 | 0 | 15.68M | 10.56M | 17.96M | 107.94M | 91.65M | 82.97M | 72.58M | 225.87M |
| Deferred Tax Liabilities | -6.76M | -5.03M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 12.35M | 9.64M | 502K | 1M | 11.49M | 1.44M | 16.24M | 1.84M | 2.08M | 8.19M |
| Total Liabilities | 128.82M | 168.52M | 180.76M | 168.19M | 223.35M | 338M | 403.46M | 126.03M | 93.97M | 91.12M |
| Total Debt | 8.99M | 7.25M | 44.78M | 40.77M | 49.21M | 162.59M | 198.78M | 91.64M | 82.97M | 80.5M |
| Net Debt | -27.1M | -78.57M | -20.35M | -75.28M | -130.79M | -440K | 70.82M | 60.85M | 37.2M | 50.66M |
| Debt / Equity | 0.15x | - | - | 0.23x | 0.37x | 15.08x | - | 6.65x | 1.88x | 1.88x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.97x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.61x |
| Interest Coverage | -56.21x | -84.42x | -139.00x | -29.48x | -21.54x | -29.50x | -14.24x | - | - | - |
| Total Equity | 60.7M▲ 0% | -48.05M▼ 179.2% | -48.32M▼ 0.6% | 174.75M▲ 461.6% | 131.51M▼ 24.7% | 10.78M▼ 91.8% | -44.86M▼ 516.0% | 13.78M▲ 130.7% | 44.22M▲ 220.8% | 26.5M▲ 0% |
| Equity Growth % | -54.23% | -179.15% | -0.58% | 461.62% | -24.75% | -91.8% | -515.99% | 130.73% | 220.79% | 393.83% |
| Book Value per Share | 30.01 | -23.58 | -17.06 | 43.80 | 28.68 | 2.00 | -7.01 | 1.77 | 4.99 | 2.77 |
| Total Shareholders' Equity | 60.7M | -48.05M | -48.32M | 174.75M | 131.51M | 10.78M | -44.86M | 13.78M | 44.22M | 26.5M |
| Common Stock | 40K | 41K | 70K | 91K | 92K | 125K | 135K | 173K | 10K | 10K |
| Retained Earnings | -263.57M | -389.37M | -459.65M | -548.78M | -614.35M | -864.51M | -978.24M | -978.1M | -972.4M | -992.32M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -146K | -20.3M | 0 | -47K | -60K | -12K | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MCRB Cash Flow Statement
Seres Therapeutics, Inc. (MCRB) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -75.52M | -62.85M | -76.52M | -93.61M | 6.69M | -228.82M | -117.35M | -148.61M | 1.12M | 1.12M |
| Operating CF Margin % | -235.27% | -222.36% | -221.76% | -281.83% | 4.61% | - | - | - | 141.57% | - |
| Operating CF Growth % | -271.95% | 16.78% | -21.74% | -22.33% | 107.14% | -3521.29% | 48.71% | -26.63% | 100.75% | 74.35% |
| Net Income | -89.38M | -98.94M | -70.28M | -89.13M | -65.58M | -250.16M | -113.72M | 136K | 5.7M | -46.9M |
| Depreciation & Amortization | 7.26M | 7.86M | 7.6M | 6.58M | 5.95M | 6.63M | 6.24M | 5.47M | 4.13M | 3.84M |
| Stock-Based Compensation | 17.36M | 16.64M | 8.34M | 8.82M | 20.22M | 25.48M | 34.1M | 20.97M | 10.84M | 7.3M |
| Deferred Taxes | 0 | 0 | 103K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -213K | -214K | 2.34M | 3.31M | 4.57M | 7.62M | 15M | -109.67M | 8.23M | 9.67M |
| Working Capital Changes | -10.55M | 11.8M | -24.63M | -23.2M | 41.53M | -18.39M | -58.98M | -65.51M | -27.78M | -16.07M |
| Change in Receivables | 0 | 0 | -1.78M | -7.6M | 9.39M | 0 | -8.67M | -2.07M | 1.55M | 2.6M |
| Change in Inventory | 0 | 0 | -3.86M | -2.87M | 0 | 0 | -29.65M | -33.8M | 0 | 0 |
| Change in Payables | -856K | -353K | -1.46M | -1.16M | 9.36M | 2.2M | -11.58M | -2.94M | -2.4M | 225K |
| Cash from Investing | 56.99M | 112.32M | -30.52M | -158.89M | 64.09M | 82.43M | 10.58M | 142.29M | -42K | -8K |
| Capital Expenditures | -4.68M | -1.94M | -1M | -591K | -9.57M | -9.82M | -7.97M | -380K | -252K | -218K |
| CapEx % of Revenue | 14.57% | 6.85% | 2.9% | 1.78% | 6.6% | - | - | - | 31.94% | - |
| Acquisitions | 0 | 0 | 29.52M | 19.9M | 0 | -92.25M | 0 | 0 | 210K | 210K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -113K | 114.25M | -29.52M | -19.9M | 0 | 92.25M | 0 | -13.52M | 0 | 0 |
| Cash from Financing | 83K | 268K | 86.23M | 303.42M | 1.18M | 129.6M | 71.7M | -90.37M | 13.9M | 13.15M |
| Debt Issued (Net) | 0 | 0 | 25M | 19.9M | -948K | 25.7M | 50.52M | -127.91M | 0 | 0 |
| Equity Issued (Net) | -33K | -136K | 61.22M | 268.64M | 0 | 101.17M | 18.16M | 23.53M | 13.9M | 12.72M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -33K | -197K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 116K | 404K | 16K | 14.88M | 2.13M | 2.73M | 3.03M | 14M | 0 | 428K |
| Net Change in Cash | -18.45M▲ 0% | 49.73M▲ 369.5% | -20.81M▼ 141.8% | 50.92M▲ 344.7% | 71.95M▲ 41.3% | -16.79M▼ 123.3% | -35.06M▼ 108.9% | -96.69M▼ 175.7% | 14.97M▲ 115.5% | -29.02M▲ 0% |
| Free Cash Flow | -80.2M▲ 0% | -64.79M▲ 19.2% | -77.52M▼ 19.6% | -94.2M▼ 21.5% | -2.88M▲ 96.9% | -238.64M▼ 8191.8% | -125.33M▲ 47.5% | -148.99M▼ 18.9% | 865K▲ 100.6% | -42.37M▲ 0% |
| FCF Margin % | -249.84% | -229.21% | -224.67% | -283.61% | -1.99% | - | - | - | 109.63% | -3694.07% |
| FCF Growth % | -457.57% | 19.21% | -19.65% | -21.52% | 96.94% | -8191.77% | 47.48% | -18.88% | 100.58% | 51.19% |
| FCF per Share | -39.65 | -31.80 | -27.37 | -23.61 | -0.63 | -44.16 | -19.58 | -19.17 | 0.10 | 0.10 |
| FCF Conversion (FCF/Net Income) | 0.84x | 0.64x | 1.09x | 1.05x | -0.10x | 0.91x | 1.03x | -1092.71x | 0.20x | 0.90x |
| Interest Paid | 0 | 0 | 0 | 0 | 2.45M | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MCRB Key Ratios
Seres Therapeutics, Inc. (MCRB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -92.46% | -1563.81% | - | -140.99% | -42.83% | -351.62% | - | 0.99% | 19.64% | -127.3% |
| Return on Invested Capital (ROIC) | -111.98% | - | - | -429.2% | -96.56% | -2440.28% | -806.07% | -180.9% | -90.33% | -90.33% |
| Gross Margin | -178.68% | -239.46% | 100% | -172.68% | 100% | - | - | - | -423.83% | 15.95% |
| Net Margin | -278.44% | -350.03% | -203.68% | -268.33% | -45.25% | - | - | - | 721.93% | -4088.84% |
| Debt / Equity | 0.15x | - | - | 0.23x | 0.37x | 15.08x | - | 6.65x | 1.88x | 1.88x |
| Interest Coverage | -56.21x | -84.42x | -139.00x | -29.48x | -21.54x | -29.50x | -14.24x | - | - | - |
| FCF Conversion | 0.84x | 0.64x | 1.09x | 1.05x | -0.10x | 0.91x | 1.03x | -1092.71x | 0.20x | 0.90x |
| Revenue Growth | 47.48% | -11.94% | 22.07% | -3.74% | 336.33% | -100% | - | - | - | - |
MCRB SEC Filings & Documents
Seres Therapeutics, Inc. (MCRB) SEC filings — annual & quarterly reports (10-K, 10-Q)
MCRB Frequently Asked Questions
Seres Therapeutics, Inc. (MCRB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Seres Therapeutics, Inc. (MCRB) reported $1.1M in revenue for fiscal year 2025.
Seres Therapeutics, Inc. (MCRB) grew revenue by 0.0% over the past year. Growth has been modest.
Seres Therapeutics, Inc. (MCRB) reported a net loss of $46.9M for fiscal year 2025.
Dividend & Returns
Seres Therapeutics, Inc. (MCRB) has a return on equity (ROE) of 19.6%. This is reasonable for most industries.
Seres Therapeutics, Inc. (MCRB) had negative free cash flow of $42.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More MCRB
Seres Therapeutics, Inc. (MCRB) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates